ArticleFrontiers in oncology2023

TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck.

Jordi Rubió-Casadevall et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.